Figure 3 from Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity
Version 2 2025-04-03, 21:47
Version 1 2024-10-16, 10:20
figure
posted on 2025-04-03, 21:47 authored by Li-Wei Kuo, Lyndsey S. Crump, Kathleen O’Neill, Michelle M. Williams, Jessica L. Christenson, Nicole S. Spoelstra, Micaela Kalani Roy, Amy Argabright, Julie A. Reisz, Angelo D’Alessandro, Meher P. Boorgula, Andrew Goodspeed, Mike Bickerdike, Benjamin G. Bitler, Jennifer K. Richer<p>KD of <i>TDO2</i> can increase IDO1 expression and activity in a compensatory manner. Stable genetic KD <i>TDO2</i> (sh<i>TDO2</i>) or scramble control (shSCR) in BT549 cells. <b>A,</b> Immunoblot of TDO2 and IDO1. <b>B,</b> Catabolite level shown in peak area (mean ± SEM) of formyl-KYN and KYN as measured by steady-state metabolomics in conditioned media from BT549 with sh<i>TDO2</i> or shSCR control. <b>C,</b> Activated AhR-regulated genes <i>CYP1A1</i> and <i>CYP1B1</i> with and without shTDO2. Data are displayed as mean ± SD with one-way ANOVA analysis. *, <i>P</i> < 0.05; **, <i>P</i> < 0.01; ***, <i>P</i> < 0.001; ****, <i>P</i> < 0.0001.</p>
History
Related Materials
- 1. DOI - Is supplement to Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity
